These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 25962092)

  • 1. AACE/ACE disease state clinical review: diagnosis and management of midgut carcinoids.
    Liu EH; Solorzano CC; Katznelson L; Vinik AI; Wong R; Randolph G
    Endocr Pract; 2015 May; 21(5):534-545. PubMed ID: 25962092
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotide.
    Ricci S; Antonuzzo A; Galli L; Ferdeghini M; Bodei L; Orlandini C; Conte PF
    Ann Oncol; 2000 Sep; 11(9):1127-30. PubMed ID: 11061606
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuroendocrine tumours of the small intestine.
    Strosberg J
    Best Pract Res Clin Gastroenterol; 2012 Dec; 26(6):755-73. PubMed ID: 23582917
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-acting depot lanreotide in the treatment of patients with advanced neuroendocrine tumors.
    Ricci S; Antonuzzo A; Galli L; Orlandini C; Ferdeghini M; Boni G; Roncella M; Mosca F; Conte PF
    Am J Clin Oncol; 2000 Aug; 23(4):412-5. PubMed ID: 10955874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance.
    O'Toole D; Ducreux M; Bommelaer G; Wemeau JL; Bouché O; Catus F; Blumberg J; Ruszniewski P
    Cancer; 2000 Feb; 88(4):770-6. PubMed ID: 10679645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A stepwise approach to the management of metastatic midgut carcinoid tumor.
    Bhattacharyya S; Gujral DM; Toumpanakis C; Dreyfus G; Davidson BR; Davar J; Caplin ME
    Nat Rev Clin Oncol; 2009 Jul; 6(7):429-33. PubMed ID: 19561636
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical scenario 2: Exploring treatment options for patients with symptomatic, progressive GEP-NETs.
    Pape UF
    Clin Adv Hematol Oncol; 2014 Dec; 12(12 Suppl 19):20-2. PubMed ID: 25768106
    [No Abstract]   [Full Text] [Related]  

  • 8. [Surgical treatment of gastric, enteric, and pancreatic endocrine tumors Part 1. Treatment of primary endocrine tumors].
    Kianmanesh R; O'toole D; Sauvanet A; Ruszniewski P; Belghiti J
    J Chir (Paris); 2005; 142(3):132-49. PubMed ID: 16142076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Carcinoid abdominal crisis: a case report.
    Jacobs RE; Bai S; Hindman N; Shah PC
    J Surg Oncol; 2014 Sep; 110(3):348-51. PubMed ID: 24860963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current diagnosis and treatment of gastrointestinal carcinoids in a series of 101 patients: the significance of serum chromogranin-A, somatostatin receptor scintigraphy and somatostatin analogues.
    Nikou GC; Lygidakis NJ; Toubanakis C; Pavlatos S; Tseleni-Balafouta S; Giannatou E; Mallas E; Safioleas M
    Hepatogastroenterology; 2005; 52(63):731-41. PubMed ID: 15966194
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LANREOTIDE THERAPY IN CARCINOID SYNDROME: PROSPECTIVE ANALYSIS OF PATIENT-REPORTED SYMPTOMS IN PATIENTS RESPONSIVE TO PRIOR OCTREOTIDE THERAPY AND PATIENTS NAÏVE TO SOMATOSTATIN ANALOGUE THERAPY IN THE ELECT PHASE 3 STUDY.
    Fisher GA; Wolin EM; Liyanage N; Lowenthal SP; Mirakhur B; Pommier RF; Shaheen M; Vinik AI;
    Endocr Pract; 2018 Mar; 24(3):243-255. PubMed ID: 29547049
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of midgut carcinoids.
    Akerström G; Hellman P; Hessman O; Osmak L
    J Surg Oncol; 2005 Mar; 89(3):161-9. PubMed ID: 15719373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of Diarrhea in Patients With Carcinoid Syndrome.
    Naraev BG; Halland M; Halperin DM; Purvis AJ; OʼDorisio TM; Halfdanarson TR
    Pancreas; 2019 Sep; 48(8):961-972. PubMed ID: 31425482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Carcinoid of the pancreas.
    Migliori M; Tomassetti P; Lalli S; Casadei R; Santini D; Corinaldesi R; Gullo L
    Pancreatology; 2002; 2(2):163-6. PubMed ID: 12123097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Flush symptoms caused by a mesenteric carcinoid without liver metastases.
    Sonnet S; Wiesner W
    JBR-BTR; 2002; 85(5):254-6. PubMed ID: 12463502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of surgery on the outcome of midgut carcinoid disease with lymph node and liver metastases.
    Hellman P; Lundström T; Ohrvall U; Eriksson B; Skogseid B; Oberg K; Tiensuu Janson E; Akerström G
    World J Surg; 2002 Aug; 26(8):991-7. PubMed ID: 12016480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient-Reported Symptom Control of Diarrhea and Flushing in Patients with Neuroendocrine Tumors Treated with Lanreotide Depot/Autogel: Results from a Randomized, Placebo-Controlled, Double-Blind and 32-Week Open-Label Study.
    Fisher GA; Wolin EM; Liyanage N; Pitman Lowenthal S; Mirakhur B; Pommier RF; Shaheen M; Vinik A;
    Oncologist; 2018 Jan; 23(1):16-24. PubMed ID: 29038234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New and Emerging Treatment Options for Gastroenteropancreatic Neuroendocrine Tumors.
    Phan AT; Kunz PL; Reidy-Lagunes DL
    Clin Adv Hematol Oncol; 2015 May; 13(5 Suppl 5):1-18; quiz 1 p following 18. PubMed ID: 26430956
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Developments in diagnosis and treatment of metastatic midgut carcinoid tumors. A review.
    Taal BG; Smits M
    Minerva Gastroenterol Dietol; 2005 Dec; 51(4):335-44. PubMed ID: 16282961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An update of lanreotide acetate for treatment of adults with carcinoid syndrome.
    Guadalupe E; Deshpande HA; Stein SM
    Drugs Today (Barc); 2018 Aug; 54(8):457-465. PubMed ID: 30209440
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.